About www.overt.bio

OverT Bio develops programmed, off-the-shelf cell therapies designed to treat solid tumors. The company utilizes AI-powered discovery of genetic programs and advanced receptor engineering to enhance T cell persistence and tumor-killing function. By leveraging gamma delta T cells, OverT Bio aims to deliver scalable, accessible treatments with the curative potential of cell therapy.

```xml <problem> Current cancer immunotherapies often face challenges due to tumor-induced barriers that limit the efficacy and durability of immune cell responses. These barriers prevent immune cells from effectively infiltrating and eliminating tumors, leading to treatment resistance and disease progression. </problem> <solution> OverT Bio engineers cell therapies with novel genetic modifications designed to overcome tumor-induced barriers and enhance immune cell function within the tumor microenvironment. By modifying immune cells, OverT Bio aims to improve their ability to recognize, infiltrate, and destroy cancer cells, leading to more effective and durable anti-tumor responses. This approach seeks to create a new generation of immunotherapies that can address the limitations of existing treatments and provide long-term benefits for patients with cancer. The company focuses on developing cell therapies that can persist and function effectively even in the face of immunosuppressive signals from the tumor. </solution> <features> - Novel genetic modifications to enhance immune cell infiltration into tumors - Engineered cell therapies designed to overcome tumor-induced immunosuppression - Enhanced recognition and killing of cancer cells by modified immune cells - Development of durable and long-lasting anti-tumor responses </features> <target_audience> OverT Bio's primary target audience includes cancer patients who are not responding to current immunotherapies, as well as oncologists and researchers seeking more effective and durable treatment options. </target_audience> ```

What does www.overt.bio do?

How much funding has www.overt.bio raised?

www.overt.bio has raised $28.5M.

www.overt.bio

Updated 2 months ago

Funding

$28.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

Funding rounds are not available yet.

Founders

Founder details are not available yet.

Product

Problem

Current cancer immunotherapies often face challenges due to tumor-induced barriers that limit the efficacy and durability of immune cell responses. These barriers prevent immune cells from effectively infiltrating and eliminating tumors, leading to treatment resistance and disease progression.

Solution

OverT Bio engineers cell therapies with novel genetic modifications designed to overcome tumor-induced barriers and enhance immune cell function within the tumor microenvironment. By modifying immune cells, OverT Bio aims to improve their ability to recognize, infiltrate, and destroy cancer cells, leading to more effective and durable anti-tumor responses. This approach seeks to create a new generation of immunotherapies that can address the limitations of existing treatments and provide long-term benefits for patients with cancer. The company focuses on developing cell therapies that can persist and function effectively even in the face of immunosuppressive signals from the tumor.

Target Audience

OverT Bio's primary target audience includes cancer patients who are not responding to current immunotherapies, as well as oncologists and researchers seeking more effective and durable treatment options.

Features

Novel genetic modifications to enhance immune cell infiltration into tumors
Engineered cell therapies designed to overcome tumor-induced immunosuppression
Enhanced recognition and killing of cancer cells by modified immune cells
Development of durable and long-lasting anti-tumor responses